FDA approves migraine injection for children as young as six

The U.S. Food and Drug Administration (FDA) has approved the first biological treatment designed to prevent migraines in children and adolescents aged 6 to 17. The newly approved therapy is administered once a month via injection and can be given either at home or in a clinic.

This breakthrough aims to reduce the frequency of migraine attacks and lessen their impact on a child’s daily routine, including school attendance, sleep, and social activities. It marks the first FDA-approved biological option for managing migraines in such a young age group.

The decision follows clinical trials that showed a significant decrease in the number of migraine days among children receiving the treatment compared to those given a placebo. Experts say early intervention may improve long-term quality of life and reduce reliance on traditional pain medications.

Pediatric migraines are a serious neurological condition, not merely a headache. They often involve nausea, light and sound sensitivity, and concentration difficulties. The newly approved therapy represents a major step toward more personalized and effective care for young patients.